Shanghai Hengrui Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Jiangsu HengRui Medicine Co., Ltd.

The registry lists 59 studies whose lead sponsor is Shanghai Hengrui Pharmaceutical Co., Ltd.. 29 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 59. List all 59 → · All Jiangsu HengRui Medicine Co., Ltd. studies →

• A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLCRecruitingNCT07798947Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-7787 Injection in Patients With Advanced Solid TumorsRecruitingNCT06605222Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingNCT06417554Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase I Study of SHR-3836 in Patients With Multiple MyelomaRecruitingNCT07490613Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06649292Phase 3

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT06474455Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant TumorsRecruitingNCT07073534Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid TumorsRecruitingNCT07296341Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid TumorsRecruitingNCT07268040Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid TumorRecruitingNCT06350006Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06512051Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid TumorsRecruitingNCT07229586Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingNCT07229729Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid TumorsRecruitingNCT05836948Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Phase I Study of SHR-A2102 in Patients With Advanced Solid TumorsRecruitingNCT05701709Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaRecruitingNCT06738251Phase 3

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid TumorsRecruitingNCT06895928Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBCRecruitingNCT05410730Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal CancerRecruitingNCT06474468Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 for Treatment of Advanced Gynecological MalignancyRecruitingNCT06654440Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)RecruitingNCT06108492Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsNot yet recruitingNCT06704828Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial CarcinomaRecruitingNCT06639347Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06589778Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid TumorsRecruitingNCT06439589Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's LymphomaRecruitingNCT06104553Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-A1912 for Injection in Patients With B Cell LymphomasEnrolling by invitationNCT05113069Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsRecruitingNCT05794477Phase 1/2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.RecruitingNCT05735275Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaCompletedNCT05593250Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of Single and Multiple Doses of HRS-6257 in Healthy SubjectsCompletedNCT07301333Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITISCompletedNCT05197023Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-7367 in Subjects With Advanced Solid TumorsCompletedNCT05740202Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast CancerActive, not recruitingNCT04993430Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical TrialCompletedNCT06236295Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease PatientsTerminatedNCT06199037Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's DiseaseCompletedNCT05681819Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisCompletedNCT05549947Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary HyperparathyroidismCompletedNCT06877247Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic DermatitisCompletedNCT06012812Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• The Trial of SHR6508 in Secondary HyperparathyroidismCompletedNCT06434961Phase 3

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee ArthroplastyTerminatedNCT05203705Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-A1909 in Subjects With Advanced Malignant TumorsCompletedNCT05162469Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of SHR-A1904 in Patients With Advanced Solid CancerActive, not recruitingNCT04877717Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of HR19024 in Subjects With Advanced Solid TumorCompletedNCT05463432Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant TumorsCompletedNCT05144061Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKATerminatedNCT06509958Phase 2

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild AsthmaCompletedNCT04905602Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of HRS2543 in Patients With Advanced TumorsTerminatedNCT05068856Phase 1

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.

• A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing HemorrhoidectomyCompletedNCT05769855Phase 3

  Sponsor listed in the registry: Shanghai Hengrui Pharmaceutical Co., Ltd.